ID   HCK_HUMAN               Reviewed;         526 AA.
AC   P08631; B4DQB6; Q29RX1; Q2VPE2; Q504R5; Q5T7K1; Q5T7K2; Q96CC0;
AC   Q9H5Y5; Q9NUA4; Q9UMJ5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 5.
DT   02-NOV-2010, entry version 152.
DE   RecName: Full=Tyrosine-protein kinase HCK;
DE            EC=2.7.10.2;
DE   AltName: Full=Hemopoietic cell kinase;
DE   AltName: Full=p59-HCK/p60-HCK;
GN   Name=HCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P60-HCK).
RX   MEDLINE=87257942; PubMed=3496523;
RA   Quintrell N., Lebo R., Varmus H., Bishop J.M., Pettenati M.J.,
RA   le Beau M.M., Diaz M.O., Rowley J.D.;
RT   "Identification of a human gene (HCK) that encodes a protein-tyrosine
RT   kinase and is expressed in hemopoietic cells.";
RL   Mol. Cell. Biol. 7:2267-2275(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P59-HCK).
RX   MEDLINE=87257943; PubMed=3453117;
RA   Ziegler S.F., Marth J.D., Lewis D.B., Perlmutter R.M.;
RT   "Novel protein-tyrosine kinase gene (hck) preferentially expressed in
RT   cells of hematopoietic origin.";
RL   Mol. Cell. Biol. 7:2276-2285(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS P60-HCK AND P59-HCK).
RC   TISSUE=Ileal mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=21638749; PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS P60-HCK AND P59-HCK).
RC   TISSUE=B-cell, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM P60-HCK), AND ALTERNATIVE
RP   INITIATION.
RC   TISSUE=Bone marrow;
RX   MEDLINE=91342636; PubMed=1875927;
RA   Lock P., Ralph S., Stanley E., Boulet I., Ramsay R., Dunn A.R.;
RT   "Two isoforms of murine hck, generated by utilization of alternative
RT   translational initiation codons, exhibit different patterns of
RT   subcellular localization.";
RL   Mol. Cell. Biol. 11:4363-4370(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 178-526.
RC   TISSUE=Spleen;
RX   MEDLINE=92241680; PubMed=1572549; DOI=10.1016/0378-1119(92)90407-G;
RA   Hradetzky D., Strebhardt K., Ruesamen-Waigmann H.;
RT   "The genomic locus of the human hemopoietic-specific cell protein
RT   tyrosine kinase (PTK)-encoding gene (HCK) confirms conservation of
RT   exon-intron structure among human PTKs of the src family.";
RL   Gene 113:275-280(1992).
RN   [9]
RP   SUBCELLULAR LOCATION, MYRISTOYLATION, PALMITOYLATION, AND MUTAGENESIS
RP   OF GLY-3; GLY-23 AND CYS-24.
RX   PubMed=7791757;
RA   Robbins S.M., Quintrell N.A., Bishop J.M.;
RT   "Myristoylation and differential palmitoylation of the HCK protein-
RT   tyrosine kinases govern their attachment to membranes and association
RT   with caveolae.";
RL   Mol. Cell. Biol. 15:3507-3515(1995).
RN   [10]
RP   INTERACTION WITH HIV-1 NEF.
RX   MEDLINE=97364702; PubMed=9218412; DOI=10.1074/jbc.272.29.17899;
RA   Briggs S.D., Sharkey M., Stevenson M., Smithgall T.E.;
RT   "SH3-mediated Hck tyrosine kinase activation and fibroblast
RT   transformation by the Nef protein of HIV-1.";
RL   J. Biol. Chem. 272:17899-17902(1997).
RN   [11]
RP   INTERACTION WITH HIV-1 VIF.
RX   PubMed=11278465; DOI=10.1074/jbc.M009076200;
RA   Hassaine G., Courcoul M., Bessou G., Barthalay Y., Picard C.,
RA   Olive D., Collette Y., Vigne R., Decroly E.;
RT   "The tyrosine kinase Hck is an inhibitor of HIV-1 replication
RT   counteracted by the viral vif protein.";
RL   J. Biol. Chem. 276:16885-16893(2001).
RN   [12]
RP   INTERACTION WITH HEV ORF3 PROTEIN.
RX   PubMed=11518702; DOI=10.1074/jbc.M101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains
RT   and activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-411, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-209, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-411, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [16]
RP   INTERACTION WITH ADAM15.
RX   PubMed=19718658; DOI=10.1002/jcb.22317;
RA   Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.;
RT   "Alternative splicing of ADAM15 regulates its interactions with
RT   cellular SH3 proteins.";
RL   J. Cell. Biochem. 108:877-885(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-36; TYR-51; TYR-127;
RP   THR-202; TYR-209; TYR-330; TYR-411; SER-462; TYR-515; SER-520 AND
RP   TYR-522, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 78-526.
RX   MEDLINE=97177106; PubMed=9024658; DOI=10.1038/385602a0;
RA   Sicheri F., Moarefi I., Kuriyan J.;
RT   "Crystal structure of the Src family tyrosine kinase Hck.";
RL   Nature 385:602-609(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 81-137.
RX   MEDLINE=98453315; PubMed=9778343; DOI=10.1021/bi980989q;
RA   Arold S., O'Brien R., Franken P., Strub M.-P., Hoh F., Dumas C.,
RA   Ladbury J.E.;
RT   "RT loop flexibility enhances the specificity of Src family SH3
RT   domains for HIV-1 Nef.";
RL   Biochemistry 37:14683-14691(1998).
RN   [20]
RP   STRUCTURE BY NMR OF 78-138.
RX   MEDLINE=98239731; PubMed=9571048; DOI=10.1006/jmbi.1998.1690;
RA   Horita D.A., Baldisseri D.M., Zhang W., Altieri A.S., Smithgall T.E.,
RA   Gmeiner W.H., Byrd R.A.;
RT   "Solution structure of the human Hck SH3 domain and identification of
RT   its ligand binding site.";
RL   J. Mol. Biol. 278:253-265(1998).
RN   [21]
RP   STRUCTURE BY NMR OF 139-245.
RX   MEDLINE=97263487; PubMed=9109402; DOI=10.1016/S0014-5793(97)00255-X;
RA   Zhang W., Smithgall T.E., Gmeiner W.H.;
RT   "Sequential assignment and secondary structure determination for the
RT   Src homology 2 domain of hematopoietic cellular kinase.";
RL   FEBS Lett. 406:131-135(1997).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-44; LEU-105 AND GLY-399.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: May serve as part of a signaling pathway coupling the Fc
CC       receptor to the activation of the respiratory burst. May also
CC       contribute to neutrophil migration and may regulate the
CC       degranulation process of neutrophils.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: May interact (via SH3 domain) with HIV-1 Nef and Vif.
CC       This interaction would stimulates its tyrosine-kinase activity.
CC       Interacts (via SH3 domain) with HEV ORF3 protein. Interacts with
CC       ADAM15.
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-346340, EBI-710506;
CC       P26660:- (xeno); NbExp=1; IntAct=EBI-346340, EBI-706322;
CC       P27958:- (xeno); NbExp=5; IntAct=EBI-346340, EBI-706378;
CC       Q9WMX2:- (xeno); NbExp=1; IntAct=EBI-346340, EBI-710918;
CC       Q9ULH1:ASAP1; NbExp=1; IntAct=EBI-346340, EBI-346622;
CC       Q9H6R7:C2orf44; NbExp=1; IntAct=EBI-346340, EBI-346906;
CC       Q9Y5K6:CD2AP; NbExp=1; IntAct=EBI-346340, EBI-298152;
CC       P50570:DNM2; NbExp=1; IntAct=EBI-346340, EBI-346547;
CC       Q92556:ELMO1; NbExp=4; IntAct=EBI-346340, EBI-346417;
CC       Q9UI08:EVL; NbExp=1; IntAct=EBI-346340, EBI-346653;
CC       P48023:FASLG; NbExp=1; IntAct=EBI-346340, EBI-495538;
CC       P61978:HNRNPK; NbExp=1; IntAct=EBI-346340, EBI-304185;
CC       Q92835:INPP5D; NbExp=1; IntAct=EBI-346340, EBI-1380477;
CC       Q07666:KHDRBS1; NbExp=2; IntAct=EBI-346340, EBI-1364;
CC       Q13094:LCP2; NbExp=1; IntAct=EBI-346340, EBI-346946;
CC       P19338:NCL; NbExp=1; IntAct=EBI-346340, EBI-346967;
CC       P27986:PIK3R1; NbExp=1; IntAct=EBI-346340, EBI-79464;
CC       O00459:PIK3R2; NbExp=1; IntAct=EBI-346340, EBI-346930;
CC       Q15393:SF3B3; NbExp=1; IntAct=EBI-346340, EBI-346977;
CC       Q9Y3L3:SH3BP1; NbExp=1; IntAct=EBI-346340, EBI-346869;
CC       Q96B97:SH3KBP1; NbExp=1; IntAct=EBI-346340, EBI-346595;
CC       Q07889:SOS1; NbExp=1; IntAct=EBI-346340, EBI-297487;
CC       Q99816:TSG101; NbExp=1; IntAct=EBI-346340, EBI-346882;
CC       P12504:vif (xeno); NbExp=3; IntAct=EBI-346340, EBI-779991;
CC       P42768:WAS; NbExp=2; IntAct=EBI-346340, EBI-346375;
CC       O43516:WIPF1; NbExp=3; IntAct=EBI-346340, EBI-346356;
CC   -!- SUBCELLULAR LOCATION: Isoform p59-HCK: Membrane; Lipid-anchor.
CC       Membrane, caveola. Note=20% of this isoform is associated with
CC       caveolae, this association depends on palmitoylation of cyteine at
CC       position 3.
CC   -!- SUBCELLULAR LOCATION: Isoform p60-HCK: Membrane; Lipid-anchor.
CC       Cytoplasm. Note=At least half of this isoform is found in the
CC       cytoplasm, some of this fraction is myristoylated.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=p60-HCK;
CC         IsoId=P08631-1; Sequence=Displayed;
CC         Note=Initiates from a CTG codon;
CC       Name=p59-HCK;
CC         IsoId=P08631-2; Sequence=VSP_018858;
CC         Note=Initiator Met-1 is removed. Contains a N-myristoyl glycine
CC         at position 2. Contains a S-palmitoyl cysteine at position 3;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in cells of the
CC       myeloid and B-lymphoid lineages.
CC   -!- DOMAIN: The SH3 domain mediates binding to HIV-1 Nef.
CC   -!- PTM: Isoform p59-HCK contains a N-myristoyl glycine at position 2.
CC       Isoform p59-HCK contains a S-palmitoyl cysteine at position 3.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52643.1; Type=Frameshift; Positions=20;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16591; AAA52643.1; ALT_FRAME; mRNA.
DR   EMBL; M16592; AAA52644.1; -; mRNA.
DR   EMBL; AK026432; BAB15482.1; -; mRNA.
DR   EMBL; AK298726; BAG60878.1; -; mRNA.
DR   EMBL; AL353092; CAI19694.1; -; Genomic_DNA.
DR   EMBL; AL049539; CAI19694.1; JOINED; Genomic_DNA.
DR   EMBL; AL353092; CAI19695.1; -; Genomic_DNA.
DR   EMBL; AL049539; CAI19695.1; JOINED; Genomic_DNA.
DR   EMBL; AL049539; CAI22966.1; -; Genomic_DNA.
DR   EMBL; AL353092; CAI22966.1; JOINED; Genomic_DNA.
DR   EMBL; AL049539; CAI22967.1; -; Genomic_DNA.
DR   EMBL; AL353092; CAI22967.1; JOINED; Genomic_DNA.
DR   EMBL; CH471077; EAW76392.1; -; Genomic_DNA.
DR   EMBL; BC014435; AAH14435.2; -; mRNA.
DR   EMBL; BC094847; AAH94847.2; -; mRNA.
DR   EMBL; BC108930; AAI08931.2; -; mRNA.
DR   EMBL; BC108931; AAI08932.2; -; mRNA.
DR   EMBL; BC113854; AAI13855.2; -; mRNA.
DR   EMBL; BC114463; AAI14464.2; -; mRNA.
DR   EMBL; X58741; CAA41565.2; -; Genomic_DNA.
DR   EMBL; X58742; CAA41565.2; JOINED; Genomic_DNA.
DR   EMBL; X58743; CAA41565.2; JOINED; Genomic_DNA.
DR   IPI; IPI00029769; -.
DR   IPI; IPI00646510; -.
DR   PIR; A27811; TVHUHC.
DR   PIR; A41263; A41263.
DR   RefSeq; NP_001165600.1; -.
DR   RefSeq; NP_001165601.1; -.
DR   RefSeq; NP_001165602.1; -.
DR   RefSeq; NP_001165604.1; -.
DR   RefSeq; NP_002101.2; -.
DR   UniGene; Hs.655210; -.
DR   PDB; 1AD5; X-ray; 2.60 A; A/B=79-526.
DR   PDB; 1BU1; X-ray; 2.60 A; A/B/C/D/E/F=81-137.
DR   PDB; 1QCF; X-ray; 2.00 A; A=81-522.
DR   PDB; 2C0I; X-ray; 2.30 A; A/B=81-522.
DR   PDB; 2C0O; X-ray; 2.85 A; A/B=81-522.
DR   PDB; 2C0T; X-ray; 2.15 A; A/B=81-522.
DR   PDB; 2HCK; X-ray; 3.00 A; A/B=79-526.
DR   PDB; 2HK5; X-ray; 2.00 A; A=247-513.
DR   PDB; 2OI3; NMR; -; A=61-140.
DR   PDB; 2OJ2; NMR; -; A=61-140.
DR   PDB; 3HCK; NMR; -; A=140-245.
DR   PDB; 3NHN; X-ray; 2.61 A; A=72-256.
DR   PDB; 4HCK; NMR; -; A=72-143.
DR   PDB; 5HCK; NMR; -; A=72-143.
DR   PDBsum; 1AD5; -.
DR   PDBsum; 1BU1; -.
DR   PDBsum; 1QCF; -.
DR   PDBsum; 2C0I; -.
DR   PDBsum; 2C0O; -.
DR   PDBsum; 2C0T; -.
DR   PDBsum; 2HCK; -.
DR   PDBsum; 2HK5; -.
DR   PDBsum; 2OI3; -.
DR   PDBsum; 2OJ2; -.
DR   PDBsum; 3HCK; -.
DR   PDBsum; 3NHN; -.
DR   PDBsum; 4HCK; -.
DR   PDBsum; 5HCK; -.
DR   ProteinModelPortal; P08631; -.
DR   DIP; DIP-1051N; -.
DR   IntAct; P08631; 48.
DR   MINT; MINT-135300; -.
DR   STRING; P08631; -.
DR   PhosphoSite; P08631; -.
DR   PRIDE; P08631; -.
DR   Ensembl; ENST00000375852; ENSP00000365012; ENSG00000101336.
DR   GeneID; 3055; -.
DR   KEGG; hsa:3055; -.
DR   UCSC; uc002wxh.1; human.
DR   UCSC; uc002wxi.1; human.
DR   CTD; 3055; -.
DR   GeneCards; GC20P030641; -.
DR   H-InvDB; HIX0015721; -.
DR   HGNC; HGNC:4840; HCK.
DR   HPA; CAB005195; -.
DR   MIM; 142370; gene.
DR   PharmGKB; PA29216; -.
DR   eggNOG; prNOG14738; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P08631; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; alphasynuclein_pathway; Alpha-synuclein signaling.
DR   Pathway_Interaction_DB; amb2_neutrophils_pathway; amb2 Integrin signaling.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; epha_fwdpathway; EPHA forward signaling.
DR   Pathway_Interaction_DB; ephrinbrevpathway; Ephrin B reverse signaling.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; il6_7pathway; IL6-mediated signaling events.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; p38alphabetapathway; Regulation of p38-alpha and p38-beta.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; txa2pathway; Thromboxane A2 receptor signaling.
DR   Reactome; REACT_6185; HIV Infection.
DR   NextBio; 12093; -.
DR   ArrayExpress; P08631; -.
DR   Bgee; P08631; -.
DR   Genevestigator; P08631; -.
DR   GermOnline; ENSG00000101336; Homo sapiens.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020748; Tyr_kinase_non-rcpt_Hck.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF259; Tyr_kinase_non-rcpt_Hck; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; ATP-binding; Complete proteome;
KW   Cytoplasm; Host-virus interaction; Kinase; Lipoprotein; Membrane;
KW   Myristate; Nucleotide-binding; Palmitate; Phosphoprotein;
KW   Polymorphism; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    526       Tyrosine-protein kinase HCK.
FT                                /FTId=PRO_0000024433.
FT   DOMAIN       78    138       SH3.
FT   DOMAIN      144    241       SH2.
FT   DOMAIN      262    515       Protein kinase.
FT   NP_BIND     268    276       ATP.
FT   ACT_SITE    381    381       Proton acceptor.
FT   BINDING     290    290       ATP.
FT   MOD_RES      36     36       Phosphothreonine.
FT   MOD_RES      51     51       Phosphotyrosine.
FT   MOD_RES     127    127       Phosphotyrosine.
FT   MOD_RES     202    202       Phosphothreonine.
FT   MOD_RES     209    209       Phosphotyrosine.
FT   MOD_RES     330    330       Phosphotyrosine.
FT   MOD_RES     411    411       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     462    462       Phosphoserine.
FT   MOD_RES     515    515       Phosphotyrosine.
FT   MOD_RES     520    520       Phosphoserine.
FT   MOD_RES     522    522       Phosphotyrosine.
FT   LIPID         2      2       N-myristoyl glycine.
FT   VAR_SEQ       1     21       Missing (in isoform p59-HCK).
FT                                /FTId=VSP_018858.
FT   VARIANT      44     44       A -> T (in dbSNP:rs56029200).
FT                                /FTId=VAR_041707.
FT   VARIANT     105    105       M -> L (in dbSNP:rs55722810).
FT                                /FTId=VAR_041708.
FT   VARIANT     399    399       D -> G (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041709.
FT   VARIANT     502    502       P -> Q (in dbSNP:rs17093828).
FT                                /FTId=VAR_033836.
FT   MUTAGEN       3      3       G->C: Slight palmitoylation, cytoplasmic
FT                                and caveolar localization; in isoform
FT                                p60-HCK;.
FT   MUTAGEN      23     23       G->A: Myristoylation and palmitoylation
FT                                are abolished, cytoplasmic and no
FT                                calveolar localization; in isoform p59-
FT                                HCK.
FT   MUTAGEN      24     24       C->S: Palmitoylation is abolished, some
FT                                cytoplasmic and no calveolar
FT                                localization; in isoform p59-HCK.
FT   CONFLICT     24     24       C -> S (in Ref. 1; AAA52643).
FT   CONFLICT     76     76       Missing (in Ref. 4; CAI19695/CAI22967 and
FT                                6; AAI13855).
FT   CONFLICT    144    144       W -> R (in Ref. 3; BAB15482).
FT   CONFLICT    378    378       I -> T (in Ref. 6; AAI13855).
FT   STRAND       82     87
FT   STRAND      104    109
FT   STRAND      114    119
FT   TURN        120    122
FT   STRAND      125    129
FT   HELIX       130    132
FT   STRAND      133    135
FT   HELIX       139    141
FT   HELIX       151    159
FT   STRAND      168    172
FT   STRAND      174    176
FT   STRAND      179    188
FT   TURN        189    191
FT   STRAND      192    202
FT   STRAND      208    214
FT   STRAND      216    218
FT   HELIX       219    226
FT   STRAND      233    235
FT   HELIX       259    261
FT   STRAND      262    269
FT   STRAND      272    281
FT   TURN        282    284
FT   STRAND      285    292
FT   HELIX       299    309
FT   STRAND      320    324
FT   STRAND      326    328
FT   STRAND      330    333
FT   HELIX       341    346
FT   HELIX       348    351
FT   HELIX       355    374
FT   HELIX       384    386
FT   STRAND      387    389
FT   STRAND      395    397
FT   HELIX       402    405
FT   HELIX       409    412
FT   STRAND      416    419
FT   HELIX       421    423
FT   HELIX       426    431
FT   HELIX       436    451
FT   HELIX       463    472
FT   HELIX       484    493
FT   HELIX       498    500
FT   HELIX       504    512
FT   STRAND      514    518
SQ   SEQUENCE   526 AA;  59600 MW;  847E877A0A641725 CRC64;
     MGGRSSCEDP GCPRDEERAP RMGCMKSKFL QVGGNTFSKT ETSASPHCPV YVPDPTSTIK
     PGPNSHNSNT PGIREAGSED IIVVALYDYE AIHHEDLSFQ KGDQMVVLEE SGEWWKARSL
     ATRKEGYIPS NYVARVDSLE TEEWFFKGIS RKDAERQLLA PGNMLGSFMI RDSETTKGSY
     SLSVRDYDPR QGDTVKHYKI RTLDNGGFYI SPRSTFSTLQ ELVDHYKKGN DGLCQKLSVP
     CMSSKPQKPW EKDAWEIPRE SLKLEKKLGA GQFGEVWMAT YNKHTKVAVK TMKPGSMSVE
     AFLAEANVMK TLQHDKLVKL HAVVTKEPIY IITEFMAKGS LLDFLKSDEG SKQPLPKLID
     FSAQIAEGMA FIEQRNYIHR DLRAANILVS ASLVCKIADF GLARVIEDNE YTAREGAKFP
     IKWTAPEAIN FGSFTIKSDV WSFGILLMEI VTYGRIPYPG MSNPEVIRAL ERGYRMPRPE
     NCPEELYNIM MRCWKNRPEE RPTFEYIQSV LDDFYTATES QYQQQP
//
